The FDA is expected to decide on treatments for acquired hypothalamic obesity, dry eye disease, primary biliary cholangitis, psoriatic arthritis, and severe leukocyte adhesion deficiency-I.
A Phase 3 clinical trial testing SGT-003, a gene therapy candidate for Duchenne muscular dystrophy (DMD), will start dosing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results